Objectives: In cost-utility analyses (CUAs) it is common to estimate the utility of patients while on treatment or when experiencing comorbidities by adjusting their baseline utility with the treatment/comorbidity-related utility decrement. This study assessed the impact of adjusting patients' baseline utility with additive versus multiplicative utility decrements on the lifetime quality-adjusted life years (QALYs) in CUAs for two chronic illnesses. MethOds: Two Markov models were developed. In the first model, utility during treatment was obtained by adjusting the baseline utility with the treatment-related utility decrement; treatment was given for one year. In the second model, utilities with comorbidities were obtained from external sources and were combined with the health state utilities by considering the lowest value. In both models, the response of the multiplicative, additive and the combined approach was investigated by comparing the number of QALYs gained over a lifetime. Results: In the first model, as treatment was only given during the first year, the impact on the number of QALYs gained over a lifetime was minimal. Thus, a similar incremental cost-effectiveness ratio per QALY (ICER/QALY) was obtained with all the approaches. In contrast, for the second model, the number of QALYs gained over a lifetime between the approaches was significantly different. This is because comorbidities were experienced during a longer period of time. Consequently, the difference in ICER/QALY was also substantial. cOnclusiOns: When developing CUA, either a multiplicative or combined, rather than additive, approach should be used to calculate the utility of patients during treatment or with comorbidities, using utility decrements, if considerable uncertainty is present in the baseline utility. However, if QALYs gained with treatment or with comorbidities represent only a small fraction of the overall QALYs gained, the difference between the approaches is not expected to have a significant impact on the results.
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UnchaRtEREd tERRItoRy -analysIs of cRoss-BoRdER sERvIcE PRovIsIon WIthIn PUBlIc hEalth systEMs
Moran P. , Teljeur C. , Murphy L. , O'Neill M. , Harrington P. , Ryan M.
Health Information and Quality Authority, Dublin, Ireland
Objectives: The European Union's (EU) 2011 Directive on cross-border health care establishes the right of EU citizens to receive treatment abroad and be reimbursed in their home country. While the focus has been on patient mobility and access, it may also facilitate international outsourcing of services between countries. This research examines the methodological challenges in evaluating the costs and consequences of cross-border service provision. MethOds: Using the example of deep brain stimulation (DBS) treatment in Ireland, we conducted an economic analysis of the provision of cross-border services from the perspective of the public health system. This included an analysis of clinical and cost-effectiveness, ethical and societal implications and the challenges of integrating care between separate health systems. Results: Accurate modelling of the provision of a new or expanded service serves as the basis for evaluating costs, impact on patients and potential gaps in continuity of care. Cost minimisation analysis may be appropriate under some circumstances, with due regard to the importance of patient selection and follow up. Cross-border services may have significant implications for equity of access, with potential negative consequences for those most in need of treatment. Results of the economic analysis indicate that a national DBS service in Ireland would cost an additional € 20,900 per patient over 10 years. The potential for anomalies within health systems with a mixture of private and public funders is highlighted, with the difference being reduced to € 4,100 per patient in a single payer scenario. cOnclusiOns: Health care funding structures can impact significantly on the cost-effectiveness of cross-border services, even when differences in the actual cost of care are minimal. Given the externalities involved, analysis from the payer perspective may be too narrow for the economic evaluation of routine cross-border provision of elective services.
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Objectives: Accurate measurement of resource use is required for economic evaluations alongside clinical trials. Patient-completed questionnaires are commonly employed as a means of collecting data; however, concerns over data quality persist, and there is little certainty about best practice. This review collates the evidence concerning the validity and reliability of resource-use measures based on patient recall with the aim of aiding health economists in developing better measures. MethOds: A search strategy incorporating terms covering health care resources, utilisation, patient-reported measures and validation/reliability concepts was applied to the MEDLINE, EMBASE and PsycINFO bibliographic databases. Studies were included if they reported original research to inform costing studies, and were about patient or proxy self-reports of direct health care-related resource use in which a comparator (to assess validity or reliability) was specified. Studies were excluded if they were not in English or if they assessed general population surveys. Reference and citation lists of included studies were hand searched to identify additional studies. Data on study and population characteristics, type of instrument, recall period and sample size were extracted. Results and conclusions concerning the validity and reliability of reports of types of resource use consumed (e.g.medication, inpatient stays) were also extracted. Results: A total of 13,367 abstracts were identified as potentially relevant through the database searches. Following abstract and full-text screening, 60 articles were deemed relevant, with a further 9 identified through hand searching. The majority focused on adults (60/69), with conventional DMARDs only. The sequence of treatments used after the failure of first biologic treatment was to be included as part of the cost-effectiveness modelling. We therefore built a model to match the treatment pathway for first-line biologics and beyond. MethOds: We researched the treatment pathway and existing cost-effectiveness models in order to create an appropriate model. We rebuilt the model used by the technology assessment group in TA195, which considered second-line biologics and beyond. We adapted this model to reflect the current treatment pathway and consider first line biologics. Results: We created a patient simulation model, which generated a cohort of virtual patients and tracked their costs and QALYs over the pathway. Patients began treatment with a biologic, and could discontinue at month 6 due to an adverse event (AE), in which case they switched to a different biologic, with first-line efficacy. Patients who did not have an AE discontinued at month 6 if their DAS 28 improvement was insufficient. After discontinuation at month 6, or later, patients next received rituximab, unless contraindicated. If rituximab was contraindicated, or the patient had an AE by month 6, they moved onto another biologic treatment, after which they received a DMARD treatment sequence (including palliative care). Patients who had insufficient DAS28 response on rituximab at month 6 switched to tocilizumab (unless received previously), after which they received the DMARD sequence. Patients who had sufficient DAS28 improvement with rituximab remained on rituximab long-term, until they received the DMARD treatment sequence. Patients could exit the model at any point if they died. cOnclusiOns: We used robust methodology and clinical rationale to assess the cost-effectiveness of licenced treatments reflected across NICE's recommended treatment pathway for RA.
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ModEllIng thE cost-EffEctIvEnEss of fIRst lInE BIologIcs foR RhEUMatoId aRthRItIs In IREland
Righetti C. 1 , Lebmeier M. 1 , Pennington B. 2 , Brereton N. J. 2 1 Uxbridge, UK, 2 BresMed, Sheffield, UK Objectives: In 2013, NCPE assessed the cost-effectiveness of subcutaneous (SC) abatacept as a first line biologic for the treatment of rheumatoid arthritis (RA), compared to existing biologics. It was necessary to consider the treatment pathway beyond first line biologics. We therefore built a model to match the treatment pathway for first line biologics and beyond. MethOds: We used our individual patient sampling model for England and Wales as a starting point to create a model which considers biologic cycling, to match the treatment pathway in Ireland. We differentiated between the efficacy of a biologic at first line, and at second line or later. Results: We created a model which could be used to calculate the costeffectiveness of biologics for the treatment of RA in Ireland. Patients first received treatment with SC abatacept, intravenous abatacept, adalimumab, etanercept, infliximab, certolizumab pegol or golimumab. If they experienced an adverse event (AE) on that treatment within 6 months, they switched to another biologic at first line efficacy. If not, their response to treatment was tested using the DAS28: if this improved by 1.2 or more, their time on treatment was sampled from a Weibull distribution, otherwise they discontinued at month 6. The patient then moved onto a randomly sampled second line biologic, which was either one of the first line biologics or rituximab. The time on second line biologic was sampled from a Weibull distribution, and then the patient moved onto a third line biologics (second line biologics and tocilizumab). The patient cycled through the biologics until they died, or had received all 8 treatments. After 8 biologics, remaining patients received leflunomide, cyclosporin, azathioprine and palliative care. cOnclusiOns: We used robust methodology and clinical rationale to model the treatment pathway of biologics for RA in Ireland and facilitated cost-effectiveness comparison between first line biologics. RTI Health Solutions, Manchester, UK, 2 Boehringer Ingelheim Ltd., Bracknell, UK, 3 Boehringer Ingelheim GmbH, Ingelheim, Germany Objectives: To perform a systematic literature review of economic evidence for genotype 1 hepatitis C virus (HCV) treatments and to summarise and assess the methods used in recent economic evaluations. MethOds: Multiple databases were searched to identify economic evaluations in patients with genotype 1 HCV. Detailed review methods are presented elsewhere. Results: 53 economic analyses and 17 Health Technology Assessment (HTA) documents were identified. Most economic analyses were performed using lifetime horizon Markov models, all for interferon-containing regimens. Most were performed in the United Kingdom (UK) (n = 13), United States (n = 13), or Germany (n = 7). Two recent National Institute for Health and Care Excellence (NICE) submissions were included: telaprevir triple therapy (with peginterferon plus ribavirin) and boceprevir triple therapy, for previously treated and untreated patients. The models used were different; however their structures and some inputs were based on previous NICE appraisals for peginterferon plus ribavirin. There were a number of limitations found in the included economic evaluations, which may have affected the cost-effectiveness outcomes: 1) The models did not adequately capture all health benefits and costs in their quality-adjusted life-year calculations; 2) The models did not account for the possibility of benefits caused by reduced transmission of HCV; 3) The models did not incorporate patient factors that may influence disease progression; 4) Modelling of subgroups may have been insufficient, particularly as the understanding of patient and viral factors that predict treatment response grows; and 5) Some made generalisations for the compensated cirrhosis population that were not comparable with the UK population. cOnclusiOns: Recent economic models have generally adhered to previous iterations of HCV models and have not evolved with our knowledge of the disease. In light of upcoming treatment alternatives, model refinement may be necessary to capture the increasingly complex treatment decisions that will be required.
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